17Jun 2022
First‐line PD‐1 Inhibitor & EGFR Blockade & Platinum‐based Chemotherapy (PEP) for Stage IV Penile Cancer

First‐line PD‐1 Inhibitor & EGFR Blockade & Platinum‐based Chemotherapy (PEP) for Stage IV Penile Cancer

To evaluate the anti‐tumor activity and the safety of anti‐PD‐1 antibody plus EGFR blockade combined with platinum‐based chemotherapy (PEP) as first‐line therapy for stage IV PSCC. PEP showed promising anti‐tumor activity, acceptable toxicity, and satisfying long‐term survival for stage IV PSCC. However, larger clinical trials are needed to validate the present study findings.

  • #urology

Like

Save

Share